• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过离子对萃取和快原子轰击质谱法对尿液中活化环磷酰胺和异环磷酰胺与美司钠的代谢物缀合物进行鉴定和定量分析。

Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.

作者信息

Manz I, Dietrich I, Przybylski M, Niemeyer U, Pohl J, Hilgard P, Brock N

出版信息

Biomed Mass Spectrom. 1985 Sep;12(9):545-53. doi: 10.1002/bms.1200120918.

DOI:10.1002/bms.1200120918
PMID:2932183
Abstract

The high bladder toxicity of the alkylating oxazaphosphorine anticancer drugs, cyclophosphamide and ifosfamide is effectively reduced by the concomitant administration of mesna (sodium 2-mercaptoethane sulphonate). The formation and rapid urinary excretion of conjugates of the activated (4-hydroxylated) oxazaphosphorine metabolites with mesna has been suggested as the pharmacological basis for the selective detoxification, but separation and identification of such metabolites in vivo have been extremely difficult due to their high polarity and chemical lability. In this study an ion-pair extraction procedure in combination with positive and negative ion fast atom bombardment mass spectrometry has been developed which enabled the identification and quantification of the conjugation products of activated oxazaphosphorine metabolites with mesna in urine. The conjugates extracted as the tetra-n-butylammonium salts are directly identified by their characteristic positive molecular ion adducts and fragment ions, and the corresponding abundant molecular anions. The pattern of molecular and fragment ion formation was established by comparison of the fast atom bombardment mass spectra of synthetic cyclophosphamide-mesna conjugates with various organic and inorganic counter ions. The ifosfamide-4-(2-thioethylsulphonate) (ifosfamide-mesna) conjugate was identified as a metabolite in the urine of rats, and in patients after administration of the combination, ifosfamide + mesna. By means of a two-step extraction and with the use of suitable analogues as internal standards, procedures for the quantification of parent oxazaphosphorine and of oxazaphosphorine-mesna conjugates by negative ion fast atom bombardment mass spectrometry have been developed, and first examples for the determination of excretion kinetics are described.

摘要

同时给予美司钠(2-巯基乙烷磺酸钠)可有效降低烷化剂氧氮磷杂环类抗癌药环磷酰胺和异环磷酰胺的高膀胱毒性。活性(4-羟基化)氧氮磷杂环类代谢物与美司钠结合物的形成及其快速经尿排泄被认为是选择性解毒的药理学基础,但由于这些代谢物的高极性和化学不稳定性,在体内分离和鉴定它们极其困难。在本研究中,开发了一种离子对萃取程序,结合正离子和负离子快原子轰击质谱法,能够鉴定和定量尿液中活性氧氮磷杂环类代谢物与美司钠的结合产物。以四正丁基铵盐形式萃取的结合物通过其特征性的正分子离子加合物和碎片离子以及相应丰富的分子阴离子直接鉴定。通过比较具有各种有机和无机抗衡离子的合成环磷酰胺-美司钠结合物的快原子轰击质谱图,确定了分子离子和碎片离子的形成模式。异环磷酰胺-4-(2-硫代乙基磺酸盐)(异环磷酰胺-美司钠)结合物在大鼠尿液中以及给予异环磷酰胺+美司钠组合后的患者尿液中被鉴定为一种代谢物。通过两步萃取并使用合适的类似物作为内标,开发了通过负离子快原子轰击质谱法定量母体氧氮磷杂环类药物和氧氮磷杂环类-美司钠结合物的程序,并描述了排泄动力学测定的首个实例。

相似文献

1
Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.通过离子对萃取和快原子轰击质谱法对尿液中活化环磷酰胺和异环磷酰胺与美司钠的代谢物缀合物进行鉴定和定量分析。
Biomed Mass Spectrom. 1985 Sep;12(9):545-53. doi: 10.1002/bms.1200120918.
2
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.接受分次静脉注射异环磷酰胺及同时应用美司钠治疗的患者尿液中异环磷酰胺、4-羟基异环磷酰胺、3-和2-去氯乙基异环磷酰胺、美司钠及二巯基丁二酸钠的排泄情况。
Cancer Chemother Pharmacol. 1997;39(5):431-9. doi: 10.1007/s002800050594.
3
The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.美司钠用于抑制环磷酰胺、异环磷酰胺及其他氮杂磷环类细胞抑制剂的尿路毒性副作用的研发。
Recent Results Cancer Res. 1980;74:270-8. doi: 10.1007/978-3-642-81488-4_32.
4
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.美司钠(2-巯基乙烷磺酸钠)作为尿路保护剂在接受进一步氮杂磷类化疗的出血性膀胱炎患者中的疗效。
J Clin Oncol. 1987 May;5(5):799-803. doi: 10.1200/JCO.1987.5.5.799.
5
Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.通过提高氧氮磷杂环类细胞抑制剂的选择性进行局部解毒来预防泌尿毒性副作用。
IARC Sci Publ. 1986(78):269-79.
6
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.巯基化合物对尿毒性氮杂磷类化合物的解毒作用。
J Cancer Res Clin Oncol. 1981;100(3):311-20. doi: 10.1007/BF00410691.
7
Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.巯乙磺酸钠(美司钠)对环磷酰胺给药后大鼠膀胱尿路上皮增殖的影响。
Urol Int. 1984;39(2):61-7. doi: 10.1159/000280947.
8
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).氮杂磷三环类细胞抑制剂的尿路毒性及其预防研究——III. 2-巯基乙烷磺酸钠(美司钠)的作用概况。
Eur J Cancer Clin Oncol. 1982 Dec;18(12):1377-87. doi: 10.1016/0277-5379(82)90143-2.
9
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].二巯基丁二酸钠预防环磷酰胺和异环磷酰胺的尿路毒性作用(初步报告)(作者译)
Arzneimittelforschung. 1982;32(5):486-7.
10
In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide--a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity.美司钠对环磷酰胺遗传毒性和毒性的体外/体内作用——一项旨在阐明美司钠抗癌活性机制的研究。
Toxicol Lett. 1988 Apr;41(1):49-56. doi: 10.1016/0378-4274(88)90007-0.

引用本文的文献

1
Mesna Improves Outcomes of Sulfur Mustard Inhalation Toxicity in an Acute Rat Model.美司钠可改善急性染硫芥吸入中毒大鼠模型的结局。
J Pharmacol Exp Ther. 2024 Jan 17;388(2):576-585. doi: 10.1124/jpet.123.001683.
2
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
3
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.异环磷酰胺及其代谢产物的临床药代动力学和药效学
Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004.
4
Ifosfamide clinical pharmacokinetics.异环磷酰胺的临床药代动力学。
Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.
5
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.美司钠预防异环磷酰胺所致泌尿系统紊乱的安慰剂对照双盲比较研究
J Cancer Res Clin Oncol. 1991;117(5):473-8. doi: 10.1007/BF01612769.